CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) was up 2.1% during mid-day trading on Friday . The company traded as high as $0.12 and last traded at $0.12. Approximately 1,859,693 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 2,111,096 shares. The stock had previously closed at $0.12.
CytoDyn Stock Performance
The stock has a 50 day moving average of $0.12 and a two-hundred day moving average of $0.14. The stock has a market cap of $145.98 million, a PE ratio of -5.95 and a beta of 0.14.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Featured Stories
- Five stocks we like better than CytoDyn
- Stock Market Upgrades: What Are They?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Best Aerospace Stocks Investing
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
